3187 studies found for:    Open Studies | "Carcinoma"
Show Display Options
Rank Status Study
21 Recruiting A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
Conditions: Advanced Adult Hepatocellular Carcinoma;   Hepatocellular Carcinoma Metastatic
Intervention: Drug: AZD9150
22 Recruiting the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
Conditions: Stage I Hepatocellular Carcinoma;   Stage II Hepatocellular Carcinoma
Interventions: Drug: the ginsenoside Rg3;   Drug: Placebo
23 Not yet recruiting Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Conditions: Poorly Differentiated Neuroendocrine Carcinoma,;   Neuroendocrine Carcinoma, Grade 3;   Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
Intervention: Drug: Everolimus (Afinitor®)
24 Recruiting Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Conditions: Clear-cell Renal Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
25 Recruiting Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients
Conditions: Cirrhosis With Hepatocellular Carcinoma;   Cirrhosis Without Hepatocellular Carcinoma
Interventions: Biological: Serum, plasma and DNA samples;   Procedure: Radiological exploration by CT scan or MRI
26 Recruiting First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Conditions: Transitional Cell Carcinoma;   Bladder Carcinoma;   Urothelial Carcinoma
Interventions: Drug: Everolimus;   Drug: Paclitaxel
27 Not yet recruiting Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy
Conditions: Bladder Cancer;   Bladder Carcinoma;   Transition Cell Cancer;   Muscle Invasive Bladder Carcinoma
Interventions: Procedure: Transurethral Resection of the Bladder Tumor & Cystoscopy;   Drug: Cisplatin;   Drug: Gemcitabine;   Radiation: Intensity Modulated Radiation Therapy;   Behavioral: Quality of Life Questionnaires;   Genetic: Urine Collection for Molecular Analysis;   Genetic: Blood Collection for Molecular Analysis
28 Recruiting Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
Condition: Non Small Cell Lung Carcinoma
Intervention:
29 Recruiting First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma;   Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Pazopanib
30 Recruiting Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
Conditions: Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions: Drug: vorinostat;   Drug: cisplatin;   Radiation: radiation therapy;   Procedure: Correlative Studies
31 Recruiting TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Conditions: Stage III Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma
Intervention: Drug: TPF induction chemotherapy
32 Recruiting A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma
Condition: Metastatic Melanoma and Merkel Cell Carcinoma
Interventions: Drug: Pasireotide sub-cutaneous formulation;   Drug: Pasireotide lon acting release formulation
33 Recruiting Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Conditions: Advanced Renal Cell Carcinoma;   Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment;   Biological: AGS-003
34 Recruiting Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
Conditions: Stage II Lymphoepithelioma of the Nasopharynx;   Stage II Squamous Cell Carcinoma of the Nasopharynx;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx
Interventions: Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
35 Not yet recruiting Autologous Dendritic Cell-Tumor Cell Immunotherapy for Advanced Epithelial Ovarian Carcinomas
Conditions: Stage III Ovarian Carcinoma;   Stage IV Ovarian Carcinoma;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Biological: ovapuldencel-T;   Biological: MC: Autologous PBMCs in GM-CSF
36 Unknown  Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
Conditions: Recurrent Nasopharyngeal Carcinoma;   Metastatic Nasopharyngeal Carcinoma
Intervention: Drug: Famitinib
37 Recruiting (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
Conditions: Ovarian Carcinoma;   Fallopian Tube Carcinoma;   Peritoneal Carcinoma
Interventions: Drug: Gemcitabine;   Drug: Bevacizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Oxaliplatin
38 Recruiting A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Conditions: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) Patients Who Are Resistant or Ineligible/Intolerant to Platinum-based Chemotherapy.;   Recurrent Head and Neck Squamous Cell Carcinoma;   Metastatic Head and Neck Squamous Cell Carcinoma
Interventions: Drug: BYL719+cetuximab;   Biological: cetuximab
39 Recruiting PANFIRE - Pilot-study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma
Conditions: Locally Advanced Pancreatic Carcinoma (LAPC);   Non-metastasized Unresectable Pancreatic Carcinoma;   Pancreatic Cancer
Intervention: Device: NanoKnife "Irreversible electroporation (IRE)"
40 Recruiting Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
Conditions: Transitional Cell Carcinoma;   Bladder Cancer;   Carcinoma in Situ;   Carcinoma in Situ Concurrent With Papillary Tumors
Interventions: Biological: CG0070 adenovirus vector;   Other: Control Arm: Quadruple Choice

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years